| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | InflaRx N.V.: InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event | 15 | GlobeNewswire (USA) | ||
| 22.04. | HV-Kalender: Aktionärs-Versammlungen u.a. bei BASF, Bayer, BP, Conti, InflaRx, L'Oreal, Munich Re, Nel ASA, SBO, Verbund | 3.133 | 4investors | Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft. In den nächsten Tagen stehen u.a. die Hauptversammlungen bei folgenden Unternehmen an. Einmal jährlich müssen sich Aufsichtsrat und... ► Artikel lesen | |
| 04.04. | InflaRx N.V. - 6-K, Report of foreign issuer | 40 | SEC Filings | ||
| 21.03. | InflaRx: Bis 2026 durchfinanziert - Verlust gestiegen | 704 | 4investors | Das Biotech-Unternehmen InflaRx meldet für das Geschäftsjahr 2023 einen Anstieg des Defizits vor Zinsen und Steuern von 32,2 Millionen Euro auf 44,9 Millionen Euro. Unter dem Strich steigt der Verlust... ► Artikel lesen | |
| 21.03. | InflaRx NV reports results for the quarter ended in December - Earnings Summary | 19 | Reuters | ||
| 21.03. | InflaRx N.V. - 20-F, Annual and transition report of foreign private issuers | 29 | SEC Filings | ||
| 21.03. | InflaRx reports FY results | 35 | Seeking Alpha | ||
| 21.03. | InflaRx N.V. - 6-K, Report of foreign issuer | 27 | SEC Filings | ||
| 21.03. | InflaRx N.V.: InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans | 16 | GlobeNewswire (USA) | ||
| 20.03. | Earnings Preview: InflaRx | 23 | Benzinga.com | ||
| 19.03. | InflaRx N.V.: InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024 | 42 | GlobeNewswire (USA) | ||
| 25.01. | InflaRx N.V. - 6-K, Report of foreign issuer | 39 | SEC Filings | ||
| 25.01. | InflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible Patients | 950 | GlobeNewswire (Europe) | InflaRx to cover costs of GOHIBIC for patients who are treated in line with its Emergency Use Authorization (EUA) but do not survive. InflaRx is determined to support broader access to GOHIBIC for... ► Artikel lesen | |
| 04.01. | InflaRx N.V. - 6-K, Report of foreign issuer | 28 | SEC Filings | ||
| 04.01. | InflaRx rises on positive trial results from its anti-inflammatory drug | 51 | Reuters | ||
| 04.01. | InflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive Results | 24 | RTTNews | ||
| 04.01. | InflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904 | 619 | GlobeNewswire (Europe) | MAD pharmacokinetic and pharmacodynamic data support best-in-class potential of INF904 over tested dose range of 30 mg once per day (QD) to 90 mg twice per day (BID) for 14 days: Achieved =90% blockade... ► Artikel lesen | |
| 06.11.23 | InflaRx startet globale Phase-3-Studie zu Vilobelimab bei seltener Hautkrankheit | 1.370 | 4investors | InflaRx führt eine Phase-3-Studie zur Wirksamkeit und Sicherheit von Vilobelimab bei Pyoderma Gangrenosum, einer seltenen entzündlichen Hautkrankheit, durch. In den USA hat das Jenaer Biotech-Unternehmen... ► Artikel lesen | |
| 06.11.23 | InflaRx N.V. - 6-K, Report of foreign issuer | 28 | SEC Filings | ||
| 06.11.23 | InflaRx N.V.: InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum | 396 | GlobeNewswire (Europe) | Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S.PG is a rare and debilitating autoimmune skin disease... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| EVOTEC | 5.740 |
| SUPER MICRO COMPUTER | 3.570 |
| BYD | 3.282 |
| BAYER | 3.187 |
| NEL | 2.735 |
| APPLE | 2.518 |
| NVIDIA | 2.466 |
| DEUTSCHE BANK | 2.304 |
| TUI | 2.263 |
| TESLA | 1.983 |
| MERCEDES-BENZ | 1.664 |
| PLUG POWER | 1.635 |
| AMAZON | 1.562 |
| VOLKSWAGEN | 1.485 |
| COMMERZBANK | 1.412 |
| RHEINMETALL | 1.347 |
| RWE | 1.325 |
| AIXTRON SE | 1.302 |
| NOVO NORDISK | 1.281 |
| DEUTSCHE LUFTHANSA | 1.244 |
| RENK GROUP | 1.235 |
| PAYPAL | 1.116 |
| BASF | 1.093 |
| SIEMENS ENERGY | 1.083 |
| PFIZER | 1.071 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
